Log In
Print
BCIQ
Print
Print this Print this
 

RDB 1419

  Manage Alerts
Collapse Summary General Information
Company Alkermes plc
DescriptionFusion protein consisting of IL-2 and IL-2R-alpha
Molecular Target Interleukin-2 (IL-2) ; Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationLung cancer
Indication DetailsTreat lung cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today